News
Kamada completes step in study of inhaled AAT with bronchiectasis patients
NESS ZIONA, Israel—Kamada, a bio-pharmaceutical company, has completed the last patient visit in a Phase II bronchiectasis study with its Inhaled Alpha-1 Antitrypsin (AAT).
The drug is delivered via an optimized Investigational eFlow Nebulizer System (PARI Pharma GmbH). Preliminary results indicate that the product continues to demonstrate a good safety profile. Final analysis of airway inflammation and secondary endpoints is expected to be available by mid-year.
David Tsur, Kamada’s CEO expressed enthusiasm at the advancement of Inhaled AAT for the treatment of bronchiectasis. “This is another milestone for Kamada in the development of Inhaled AAT. Bronchiectasis affects approximately 600,000 people world-wide1 and we believe our novel approach, which could impact the underlying inflammatory processes, may considerably improve the quality of life of these patients.”
According to Pnina Strauss, Kamada’s Clinical Trials and IP Manager, “This is the third Phase II clinical trial we have conducted with Inhaled AAT and we continue to observe a very promising safety profile.”
The double-blind, placebo-controlled study was performed at the Rabin Medical Center, Campus Beilinson in Israel.
